ECOG-ACRIN / EA2192

Official Title

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

Study Purpose

To see if treating with olaparib compared to the usual approach which is observation, 

 is more successful in preventing pancreatic cancer from coming back 

Diagnosis

Pancreatic cancer that has been surgically removed, and is known to have a special marker known as a BRCA1 or BRCA2. These markers are performed on the tumor specimen at the request of the physician

Eligibility

Pancreatic cancer that has been surgically removed, and is known to have a special marker known as a BRCA1 or BRCA2. 

 

Intervention

This study is a double blind study.  This means that the patient will receive a pill as part of the study, but the physician and patient will not know whether the pill is active drug (Olaparib) or a placebo (inactive pill).  This is done to look at whether the drug Olaparib has increased benefit in preventing the pancreatic cancer from returning compared to the usual care which is observation, or no further treatment.